These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 34187401

  • 1. A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial.
    Grunenberg A, Kaiser LM, Woelfle S, Schmelzle B, Viardot A, Möller P, Barth TFE, Muche R, Dreyhaupt J, Raderer M, Kiesewetter B, Buske C.
    BMC Cancer; 2021 Jun 29; 21(1):749. PubMed ID: 34187401
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma.
    Matasar MJ, Dreyling M, Leppä S, Santoro A, Pedersen M, Buvaylo V, Fletcher M, Childs BH, Zinzani PL.
    Clin Lymphoma Myeloma Leuk; 2021 Nov 29; 21(11):e886-e894. PubMed ID: 34389273
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
    Dreyling M, Morschhauser F, Bouabdallah K, Bron D, Cunningham D, Assouline SE, Verhoef G, Linton K, Thieblemont C, Vitolo U, Hiemeyer F, Giurescu M, Garcia-Vargas J, Gorbatchevsky I, Liu L, Koechert K, Peña C, Neves M, Childs BH, Zinzani PL.
    Ann Oncol; 2017 Sep 01; 28(9):2169-2178. PubMed ID: 28633365
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma.
    Panayiotidis P, Follows GA, Mollica L, Nagler A, Özcan M, Santoro A, Stevens D, Trevarthen D, Hiemeyer F, Garcia-Vargas J, Childs BH, Zinzani PL, Dreyling M.
    Blood Adv; 2021 Feb 09; 5(3):823-828. PubMed ID: 33560394
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial.
    Becnel MR, Nastoupil LJ, Samaniego F, Davis RE, You MJ, Green M, Hagemeister FB, Fanale MA, Fayad LE, Westin JR, Wang M, Oki Y, Forbes SG, Feng L, Neelapu SS, Fowler NH.
    Br J Haematol; 2019 Jun 09; 185(5):874-882. PubMed ID: 30919940
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.
    Gordon MJ, Feng L, Strati P, Lee HJ, Hagemeister FB, Westin JR, Samaniego F, Marques-Piubelli ML, Vega Vazquez F, Parra Cuentas ER, Solis-Soto LM, Ma W, Wang J, Claret L, Averill B, Ibanez K, Fayad LE, Flowers CR, Green MR, Davis RE, Neelapu SS, Fowler NH, Nastoupil LJ.
    Cancer; 2024 Mar 15; 130(6):876-885. PubMed ID: 37985359
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Copanlisib: First Global Approval.
    Markham A.
    Drugs; 2017 Dec 15; 77(18):2057-2062. PubMed ID: 29127587
    [Abstract] [Full Text] [Related]

  • 16. Marginal Zone Lymphoma: State-of-the-Art Treatment.
    Sindel A, Al-Juhaishi T, Yazbeck V.
    Curr Treat Options Oncol; 2019 Dec 05; 20(12):90. PubMed ID: 31807935
    [Abstract] [Full Text] [Related]

  • 17. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
    Tan ES, Cao B, Kim J, Al-Toubah TE, Mehta R, Centeno BA, Kim RD.
    Cancer; 2021 Apr 15; 127(8):1293-1300. PubMed ID: 33289918
    [Abstract] [Full Text] [Related]

  • 18. A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B-cell lymphomas.
    Vannata B, Vanazzi A, Negri M, Liptrott SJ, Bartosek AA, Miani M, Di Sanzo A, Cavalli F, Zucca E, Stathis A.
    Hematol Oncol; 2021 Feb 15; 39(1):60-65. PubMed ID: 33103778
    [Abstract] [Full Text] [Related]

  • 19. Phase II trial evaluating the efficacy and safety of the anti-CD20 monoclonal antibody obinutuzumab in patients with marginal zone lymphoma.
    Grunenberg A, Kaiser LM, Woelfle S, Schmelzle B, Viardot A, Möller P, Barth TF, Muche R, Dreyhaupt J, Buske C.
    Future Oncol; 2020 May 15; 16(13):817-825. PubMed ID: 32223334
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.